Long-term efficacy of 90Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms

Aim: To determine the efficacy of 90Y [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Future oncology (London, England) England), 2016-08, Vol.12 (16), p.1877
Hauptverfasser: Rogowski, Wojciech, Wachuła, Ewa, Lewczuk, Anna, Buscombe, John R, Seklecka, Nina, Sankowski, Artur, Ćwikła, Jarosław B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim: To determine the efficacy of 90Y [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Results: Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender. Conclusion:90Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2016-0031